5242802026-04-012026-06-305242802026-04-012026-06-30in-capmkt:OtherExpenses1Member5242802026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15242802026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524280KOPRANNOTLISTEDINE082A01010KOPRAN LIMITEDMain BoardEquity2026-04-012027-03-312026-08-072026-07-22INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2026-08-0710:45:002026-08-0712:40:00Declaration of unmodified opinionfalsefalseNo Default on Loans and there is no Debt Securities in the Company 2026-04-012026-06-30UnauditedStandalone6275790002913400065671300037548100042756000-102924000882850001238400013475000139418000568875000878380000878380001932500012830002060800006723000000006723000077600068006000482856000101.391.39001.391.391) The above Statement of consolidated and standalone unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act 2013, read with Companies (lndian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in lndia. There is no minority interest. <br /> 2) The above Statement of consolidated and standalone unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 7, 2026 and have been reviewed by the Statutory Auditors of the Company who have expressed unmodified opinion. <br /> 3) The Company and the subsidiaries together referred to as "Group" are engaged primarily in the pharmaceuticals business and there are no separate reportable segments as per Ind AS 108 on " Operating Segment Reporting". <br /> 4) Figures for the previous period have been regrouped or reclassified, wherever necessary to make them comparable with the figures of the current period. <br /> Other Expenses139418000Remeasurements of defined benefit plans103700010370002610000776000UnauditedtrueKhandelwal Jain & Cotrue2028-08-31